Subsets of PTEN-controlled TFAs preferentially function in specific types of tumors.
2012-02-08T01:36:00Z (GMT) by
<p>(A) t-test p-values comparing TFAs of the subgroups based on PTEN status and clustering results as shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0031053#pone-0031053-g005" target="_blank">Figure 5</a> in three tumor types. In the t-tests performed on of prostate and breast cancers, PTEN positive samples in group 3 were used as the PTEN positive functional status, the PTEN negative samples in group 1 as the PTEN negative functional status. Similarly, in brain tumor PTEN IHC positive samples in group 2 and PTEN IHC negative samples in group 1 were selected for representing PTEN positive and negative functional status respectively. The red line highlighted the 6 TFAs significantly (p<0.05) altered between tumor subgroups in three tumor types. (B) Venn diagram summarizing the overlap of the TFAs that contribute to the discrimination of tumor subgroups with different PTEN status in different tumor types. (C–D) Heatmap of the absolute Pearson correlation coefficients between NCA-inferred TF activity profiles across the tumor samples from prostate (C), breast (D) and brain (E) cancers, indicating groups of co-active transcription factors may function together.</p>